More research needed on heavy impact of antibiotic resistance, report says
A Wellcome report yesterday says more research is needed on drug-resistant bacterial infections (DRIs), but current data indicate that DRIs can be more likely to occur—and have more serious ramifications—in people with health conditions like cancer or who have received extensive treatment such as surgery.
The authors did a rapid evidence assessment of studies related to DRIs and surgery (11), organ transplants (22), cancer (10), intensive care unit admission (11), diabetes (16), HIV (15), infants/children (8), immunodeficiency (7), liver and kidney disease (3), and physical trauma such as road accidents (5).
They found that DRIs, particularly antibiotic-resistant infections, are often more likely in those with health conditions, with some studies showing that certain conditions may increase likelihood of death or health complications. However, they note a lack of DRI-related research on not only the health conditions they included in the report but also many they wanted to include, such as strokes, asthma, and childbirth.
In a first-person anecdote by Lillian Sung, MD, PhD, of the Hospital for Sick Children in Toronto in the executive summary, she talked about how physicians have needed to use stronger treatments over the years, resulting in a cycle of increasing resistance and more side effects. And even with these mitigations, she writes, children can go from being fine to dying within 12 hours because of DRIs.
Another excerpt by Paul Turner, MBBS, PhD, director of the Cambodia Oxford Medical Research Unit, touches on concerns in lower- and middle-income countries: "If you lose the use of azithromycin in places like the US and UK, maybe it doesn't seem like a big deal," he writes. "Kids with an ear infection will be able to get another antibiotic. But if we lose azithromycin in places like Cambodia or Nepal or Pakistan because of drug resistance, there is no oral treatment left for typhoid. It's the last one left."
The Wellcome authors conclude, "The trends that were identified—of links between resistant infections and greater mortality risks, for example—were overwhelmingly negative, but urgent research is needed to understand the impact of [antimicrobial resistance] and to drive an immediate and ambitious policy response."
Jul 13 Wellcome report
H5N6 avian flu infection hospitalizes Chinese man
China has reported another human H5N6 avian flu infection, this time in a 55-year-old man who lives in Bazhong City in Sichuan province, according to a statement today from Hong Kong's Centre for Health Protection (CHP).
The man's symptoms began on Jun 30, and he was hospitalized on Jul 4, where he is listed in critical condition. An investigation found that he had contact with live domestic poultry before he got sick. Sichuan province is in southwest China.
Since 2014, China's mainland has reported 32 H5N6 cases, which are often severe or fatal.
China and other countries, mostly in Asia, have reported H5N6 avian flu outbreaks in poultry, but China and Laos are the only nations to report human cases.
Jul 14 CHP statement
Zendel developing live-attenuated TB vaccines for children, adults
The Spanish pharmaceutical company Zendel has partnered with IAVI to develop a live-attenuated (weakened) tuberculosis (TB) vaccine that, if successful, could provide long-lasting protection in infants, adolescents, and adults, according to an IAVI news release today.
The vaccine candidate, called MTBVAC, will complete a phase 2 trial in adults this year. A phase 3 trial of MTBVAC in newborns is scheduled to begin in several African countries later this year, as well.
The only TB vaccine in use is bacille Calmette-Guérin (BCG), which has limited effectiveness in preventing pulmonary TB in adults. That vaccine has been used for 100 years.
IAVI, an international nonprofit research organization focused on developing vaccines and antibodies against infectious and neglected diseases, said progress on COVID-19 vaccines this year should not place developing a new and effective TB vaccine on the back burner.
"The urgency of global COVID-19 vaccine rollout is deservedly receiving unprecedented attention. At the same time, this global focus on disease control is an opportunity to go the extra mile and try to stamp out TB, which, once COVID-19 recedes, will resume its position as the leading cause of infectious disease deaths globally," said Mark Feinberg, MD, PhD, president and CEO of IAVI.
Before COVID-19, TB was the most deadly infectious disease in the world, killing 1.4 million people a year.
Jul 14 IAVI press release